Mr. Hastings joined Arbutus in June 2018 and serves as the Company’s Chief Financial Officer. Mr. Hastings has more than 25 years of executive finance and operational experience with biotech and pharma companies in various stages of development, including commercial. Mr. Hastings spent the majority of his career at Incyte Corporation where he served as Chief Financial Officer and Executive Vice President. During his tenure, Mr. Hastings oversaw all financial aspects as Incyte transitioned from research and development to commercialization, following the launch of Jakafi® (ruxolitinib). Mr. Hastings also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc., where he played an important role in ArQule’s transition into a drug discovery and development organization, and its two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Mr. Hastings held prior executive and senior level financial positions at Sepracor, Inc. and Unilife Corporation (a medical device company). Mr. Hastings is a Board member and Chair of the Audit Committees of Scynexis, Inc., and VBL Therapeutics. Mr. Hastings received his BA from the University of Vermont.